More Healthcare Coverage

  • October 15, 2024

    Law Firms Diverge As Anti-ESG Pushback Continues

    A continuing onslaught of legislation and litigation opposing corporate environmental, social and governance actions has created a fork in the road for law firms, with some choosing to scale back efforts and others pushing ahead with their internal ESG and diversity, equity and inclusion goals.

  • October 15, 2024

    The 2024 Law360 Pulse Social Impact Leaders

    Check out our Social Impact Leaders ranking, analysis and interactive graphics to see which firms stand out for their engagement with social responsibility and commitment to pro bono service.

  • October 11, 2024

    Feds Target Ill. Hospital CEO As $19M Theft Probe Widens

    A federal corruption investigation into the theft of $19 million from a Chicago hospital has widened to ensnare the hospital's chief executive, according to a new indictment handed down by an Illinois federal grand jury.

  • October 11, 2024

    Up Next At High Court: CBD Injuries & The Clean Water Act

    The U.S. Supreme Court will be closed Monday, but the justices will return to the bench Tuesday to hear arguments over whether the federal Racketeering Influenced and Corrupt Organizations Act allows litigants to pursue claims of economic harm tied to personal injuries, and how specific pollutant discharge limits have to be under the Clean Water Act.

  • October 11, 2024

    Quinn Emanuel Gets Trimmed $92M Fee In ACA Cases

    Quinn Emanuel Urquhart & Sullivan LLP will get $92 million in fees from a $3.7 billion win in two class actions against the government over risk corridor payments under the Affordable Care Act, a U.S. Court of Federal Claims judge ruled Thursday, trimming the firm's renewed $185 million request.

  • October 11, 2024

    Apple Watch Patents Dodge Ax As Masimo Jury Trial Nears

    A Delaware federal judge has refused to invalidate Apple Inc.'s smartwatch patents being challenged by health technology company Masimo Corp. ahead of this month's jury trial over whether the tech behemoth infringed Masimo's pulse oximetry technology patents.

  • October 11, 2024

    Dem AGs Urge Judge To Rule Now On FDA Abortion Pill Regs

    Washington and 16 other states with Democratic attorneys general are pressing a federal judge to force the U.S. Food and Drug Administration to lift restrictions on access to mifepristone, arguing that the agency is swayed by the controversy swirling around the abortion medication that has been proved to be safer than Tylenol, Viagra and insulin.

  • October 11, 2024

    Staffing Co. Cuts Deal To End Travel Nurses' Pay Claims

    A staffing firm agreed to pay nurses $500 each to end allegations that it lured them to work at COVID-19 testing clinics in Fort Lauderdale, Florida, by making wage promises it never fulfilled, a filing in Georgia federal court said.

  • October 10, 2024

    Animal Medication Co. Sued Over Dog Arthritis Treatment Risks

    New Jersey-based animal medication company Zoetis Inc. was hit with a proposed class action Wednesday alleging that a drug used to treat osteoarthritis in dogs has harmful effects such as seizures, inability to walk, organ damage and even death, which the company has failed to warn about.

  • October 10, 2024

    Target Made Inflated Claims About Gas Pills, Shoppers Allege

    Target customers hit the retailer with a putative class action lawsuit in New York federal court Wednesday alleging its line of Up & Up gas relief pills is not "maximum strength" as the label contends, and other similar medications have higher concentrations of key ingredients.

  • October 10, 2024

    Pfizer Lone Holdout In Senate Pharma Tax Probe, Wyden Says

    Pfizer Inc. is the only company to withhold a country-by-country breakdown of its tax planning in the Senate Finance Committee's probe into how Republicans' 2017 tax package reduced the pharmaceutical industry's U.S. liabilities, according to a letter Chairman Ron Wyden released Thursday.

  • October 09, 2024

    Biotech Co. Names Well-Traveled Former GC As Board Chair

    Virometix AG, a privately held Swiss biotechnology company developing synthetic vaccines against infectious diseases and cancer, has appointed a globe-trotting former general counsel as chair of its board of directors.  

  • October 09, 2024

    Novant Ex-Exec's Counsel Wins $154K In Fees For Race Case

    Counsel for a former Novant Health Inc. executive who won $4.3 million after accusing the company of firing him during a diversity push because he was white got $154,000 in attorney fees for successfully defending the award on appeal, slightly less than what was requested.

  • October 08, 2024

    Illumina Wants Unresponsive Plaintiff To Pay $200K, Atty Fees

    Biotechnology company Illumina Inc. asked a New Jersey federal court Tuesday to order a former graduate student to pay $200,000 in liquidated damages for allegedly failing to respond to attempts to finalize a settlement to his claims that attorneys from Latham & Watkins LLP and Akin Gump Strauss Hauer & Feld LLP manipulated a patent case to steal his intellectual property.

  • October 08, 2024

    NC Judge Scolds Clinic And Hospital Over Bids To Seal TM Case

    A North Carolina federal judge chastised a weight loss center, a hospital and a community health provider for their bids to seal a large swath of information in a trademark infringement lawsuit, invoking the secretive medieval court that gave rise to the phrase "star chamber."

  • October 08, 2024

    Mass. Seeks Order Forcing Steward To Maintain Coverage

    Massachusetts officials are asking the Texas bankruptcy judge presiding over Steward Health Care's Chapter 11 proceedings to order the company to maintain medical malpractice and workers' compensation coverage for current and potential claims from its operation of hospitals and medical practices in the Bay State.

  • October 07, 2024

    Fed. Circ. Questions If Safer OxyContin Profits Came From IP

    An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other companies had ample opportunity to reach a solution and failed to do so.

  • October 07, 2024

    Justices Won't Take Juror Family Bias Case

    The U.S. Supreme Court said Monday it won't review whether a deceased Washington woman's medical malpractice claim deserves a new trial because two prospective jurors had relatives who had been treated by one of the defendants.

  • October 04, 2024

    Top 5 Supreme Court Cases To Watch This Fall

    The U.S. Supreme Court will hear several cases in its October 2024 term that could further refine the new administrative law landscape, establish constitutional rights to gender-affirming care for transgender minors and affect how the federal government regulates water, air and weapons. Here, Law360 looks at five of the most important cases on the Supreme Court's docket so far.

  • October 04, 2024

    NJ, Ethics Board Must Hand Over Docs In Retaliation Fight

    A New Jersey state judge has ordered the state and its ethics commission to hand over to an ex-state health official internal documents in his lawsuit alleging that he was wrongly fired in 2020 for raising concerns about the earmarking of COVID-19 tests for relatives of another state official.

  • October 04, 2024

    Healthcare Co.'s Workers Get Cert. In OT Pay Row

    A Connecticut home healthcare logistics company and a former employee suing in federal court over its pay practices have agreed to conditionally certify a collective and dismiss most claims, leaving only a claim for payment of off-the-clock work.

  • October 04, 2024

    Prof. Claims Fox Chase, Temple U. Failed To Deter Harassment

    A cancer research professor has filed a sexual harassment lawsuit against Temple University Health System's Fox Chase Cancer Center, claiming in Pennsylvania federal court it failed to act on her complaints of being harassed by the eventual director, who she said went on to influence "numerous decisions" that hurt her career.

  • October 03, 2024

    Gilead Makes Generic HIV Drug Plan, Advocates Urge Expansion

    Gilead Sciences Inc. this week announced a plan to allow six drugmakers to produce generic lenacapavir to help combat the HIV pandemic in 120 lower-income countries, an initiative that won praise as a welcome step Thursday, although advocacy groups urged the company to expand the effort.

  • October 02, 2024

    NC's Med Mal Damages Cap Is Constitutional, Panel Told

    North Carolina's cap on compensatory damages in medical negligence suits does not impede a citizen's right to a jury trial and is in line with the state's constitution, according to an attorney appointed to defend the law against a woman seeking to collect her full $7.5 million jury verdict stemming from the loss of her unborn baby.

  • October 02, 2024

    Doctor Cops To Dealing Ketamine That Killed Matthew Perry

    A physician pled guilty in California federal court Wednesday to helping supply the ketamine that killed "Friends" star Matthew Perry, including by providing illegally obtained vials of the drug for Perry's personal assistant to administer at home.

Expert Analysis

  • After Chevron: ERISA Challenges To Watch

    Author Photo

    The end of Chevron deference makes the outcome of Employee Retirement Income Security Act regulatory challenges more uncertain as courts become final arbiters of pending lawsuits about ESG investments, the definition of a fiduciary, unallocated pension forfeitures and discrimination in healthcare plans, says Evelyn Haralampu at Burns & Levinson.

  • Justices' Intent Witness Ruling May Be Useful For Defense Bar

    Author Photo

    At first glance, the U.S. Supreme Court’s recent Diaz v. U.S. decision, allowing experts to testify to the mental state of criminal defendants in federal court, gives prosecutors a new tool, but creative white collar defense counsel may be able to use the same tool to their own advantage, say Jack Sharman and Rachel Bragg at Lightfoot Franklin.

  • Contract Disputes Recap: Preserving Payment Rights

    Author Photo

    Stephanie Magnell and Zachary Jacobson at Seyfarth examine three recent decisions that together illustrate the importance of keeping accurate records and adhering to contractual procedures to avoid inadvertently waiving contractual rights to cost reimbursements or nonroutine payments.

  • Think Like A Lawyer: Dance The Legal Standard Two-Step

    Author Photo

    From rookie brief writers to Chief Justice John Roberts, lawyers should master the legal standard two-step — framing the governing standard at the outset, and clarifying why they meet that standard — which has benefits for both the drafter and reader, says Luke Andrews at Poole Huffman.

  • Weight-Loss Drugs May Spur Next Major Mass Tort

    Author Photo

    With lawsuits concerning Ozempic and similar weight-loss drugs potentially becoming the next major mass tort in the U.S., companies should consider key defense strategies ranging from alternate dispute resolution to enhanced drug safety, say Dino Haloulos and Jarif Khan at Foley & Mansfield.

  • Bid Protest Spotlight: Standing, Prejudice, Conflicts

    Author Photo

    In this month's bid protest roundup, Caitlin Crujido at MoFo examines three recent decisions from the U.S. Government Accountability Office concerning whether a would-be protestor was an interested party with standing, whether an agency adequately investigated potential procurement violations and whether a proposed firewall sufficiently addressed an impaired objectivity organizational conflict of interest.

  • The FTC Needs To Challenge The Novo-Catalent Deal

    Author Photo

    Novo's acquisition of Catalent threatens to substantially lessen competition in the manufacturing and marketing of GLP-1 diabetes and obesity drugs, and the Federal Trade Commission should challenge it under a vertical theory of harm, as it aligns with last year's merger guidelines and the Fifth Circuit decision in Illumina, says attorney David Balto.

  • Being A Luthier Makes Me A Better Lawyer

    Author Photo

    When I’m not working as an appellate lawyer, I spend my spare time building guitars — a craft known as luthiery — which has helped to enhance the discipline, patience and resilience needed to write better briefs, says Rob Carty at Nichols Brar.

  • Lead Like 'Ted Lasso' By Embracing Cognitive Diversity

    Author Photo

    The Apple TV+ series “Ted Lasso” aptly illustrates how embracing cognitive diversity can be a winning strategy for teams, providing a useful lesson for law firms, which can benefit significantly from fresh, diverse perspectives and collaborative problem-solving, says Paul Manuele at PR Manuele Consulting.

  • Now More Than Ever, Lawyers Must Exhibit Professionalism

    Author Photo

    As society becomes increasingly fractured and workplace incivility is on the rise, attorneys must champion professionalism and lead by example, demonstrating how lawyers can respectfully disagree without being disagreeable, says Edward Casmere at Norton Rose.

  • Serving In The National Guard Makes Me A Better Lawyer

    Author Photo

    My ongoing military experience as a judge advocate general in the National Guard has shaped me as a person and a lawyer, teaching me the importance of embracing confidence, balance and teamwork in both my Army and civilian roles, says Danielle Aymond at Baker Donelson.

  • A Midyear Forecast: Tailwinds Expected For Atty Hourly Rates

    Author Photo

    Hourly rates for partners, associates and support staff continued to rise in the first half of this year, and this growth shows no signs of slowing for the rest of 2024 and into next year, driven in part by the return of mergers and acquisitions and the widespread adoption of artificial intelligence, says Chuck Chandler at Valeo Partners.

  • A Look At Acquisition Trends For Radiopharmaceuticals

    Author Photo

    As radiopharmaceutical drugs are increasingly used for the diagnosis and treatment of certain diseases, interest from Big Pharma entities is following suit, despite some questions around the drugs' capacity to expand beyond their limited niche, says Adrian Toutoungi at Taylor Wessing.

Can't find the article you're looking for? Click here to search the Healthcare Authority Other archive.